BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Aug 15, 2020
Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

While CBMG’s $383 million take private deal was put in motion before U.S. officials further ratcheted up pressure on U.S- listed Chinese companies, the move highlights the trade-offs Chinese companies face in considering where to...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...SVP, clinical development. Kim was CFO of VGX Pharmaceuticals Inc., which in 2009 merged with Inovio Biomedical...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

Three of four life sciences IPOs priced above expectations ahead of Friday’s session, and two biotechs in the group -- Forma and Repare -- posted big gains in their first trading day, showing continued strength...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies...
BioCentury | Jun 6, 2020
Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

Closely-watched CAR T company Legend raised more than $400 million Friday in the year's largest biotech IPO thus far. The deal helped push the total raised via life sciences IPOs to $6.2 billion, outpacing the...
Items per page:
1 - 10 of 193
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Aug 15, 2020
Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

While CBMG’s $383 million take private deal was put in motion before U.S. officials further ratcheted up pressure on U.S- listed Chinese companies, the move highlights the trade-offs Chinese companies face in considering where to...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...SVP, clinical development. Kim was CFO of VGX Pharmaceuticals Inc., which in 2009 merged with Inovio Biomedical...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

Three of four life sciences IPOs priced above expectations ahead of Friday’s session, and two biotechs in the group -- Forma and Repare -- posted big gains in their first trading day, showing continued strength...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies...
BioCentury | Jun 6, 2020
Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

Closely-watched CAR T company Legend raised more than $400 million Friday in the year's largest biotech IPO thus far. The deal helped push the total raised via life sciences IPOs to $6.2 billion, outpacing the...
Items per page:
1 - 10 of 193